Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN)

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) discovers, develops and markets biopharmaceutical products for the treatment of a variety of medical conditions.

Regeneron has generated significant investor attention because of its Covid-19 treatment candidate – a dual antibody cocktail called REGN-COV2.

Regeneron has already signed a $450 million manufacturing and supply agreement to provide doses of this cocktail to the U.S. government should it prove to be safe and effective.

To that end, on September 14, the company announced in conjunction with the University of Oxford that RECOVERY (Randomized Evaluation of COVid-19 thERapY), a major randomized clinical trial of potential Covid-19 treatments, will evaluate Regeneron’s investigational antibody cocktail, REGN-COV2.